FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?

被引:20
|
作者
Pandey, Anuradha [1 ]
Kumar, Goru Santosh [1 ]
Kadakol, Almesh [1 ]
Malek, Vajir [1 ]
Gaikwad, Anil Bhanudas [1 ]
机构
[1] Birla Inst Technol & Sci Pilani, Mol Pharmacol Lab, Dept Pharm, Pilani Campus, Pilani 333031, Rajasthan, India
关键词
FoxO1; metabolic disorders; diabetes; diabetic complications; obesity; inhibitors; AS1842856;
D O I
10.2174/1573399811666150804104858
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
FoxO1, one of the most widely expressed sub-families of the winged helix forkhead factors, is biologically ` omni-functional' owing to its far-flung roles in metabolism, cell cycle, tissue differentiation and development and oxidative stress response. The knowledge of involvement of FoxO1 in metabolic disorders has long been there, but the potential target remained underutilized due to unavailability of specific and potent inhibitors. The review provides an insight into the role of FoxO1 in orchestrating metabolic diseases' pathogenesis (including diabetes, its secondary complications and obesity) and compiles the literature on FoxO1 inhibitors. The emergence of various natural molecules and synthesized small molecules like AS1842856 as FoxO1 inhibitors urges us to think further and decide the future course of drug development for the management of metabolic disorders.
引用
收藏
页码:223 / 230
页数:8
相关论文
共 50 条
  • [31] FoxO1 and hepatic lipid metabolism
    Sparks, Janet D.
    Dong, Henry H.
    CURRENT OPINION IN LIPIDOLOGY, 2009, 20 (03) : 217 - 226
  • [32] Diabetes: Selective FOXO1 modulation
    Crunkhorn S.
    Nature Reviews Drug Discovery, 2017, 16 (12) : 828 - 828
  • [33] Cytosolic FoxO1: alive and killing
    René H. Medema
    Marja Jäättelä
    Nature Cell Biology, 2010, 12 : 642 - 643
  • [34] Isotretinoin and FoxO1 A scientific hypothesis
    Melnik, Bodo C.
    DERMATO-ENDOCRINOLOGY, 2011, 3 (03) : 141 - 165
  • [35] FoxO1: A Molecule for All Seasons
    Kousteni, Stavroula
    JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (05) : 912 - 917
  • [36] Putting the brakes on FOXO1 in fat
    Kim, Jane J.
    Fan, Wuqiang
    Olefsky, Jerrold M.
    EMBO JOURNAL, 2012, 31 (10): : 2240 - 2241
  • [37] Small molecule inhibitors of the PAX3::FOXO1 fusion protein in rhabdomyosarcoma
    Shaw, Taryn
    Nakazawa, Kay
    Tiwari, Purushottam
    Nelson, Eryn
    Formen, Jeffrey
    Wolf, Christian
    Toretsky, Jeffrey
    Uren, Aykut
    CANCER RESEARCH, 2024, 84 (06)
  • [38] Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice
    Battiprolu, Pavan K.
    Hojayev, Berdymammet
    Jiang, Nan
    Wang, Zhao V.
    Luo, Xiang
    Iglewski, Myriam
    Shelton, John M.
    Gerard, Robert D.
    Rothermel, Beverly A.
    Gillette, Thomas G.
    Lavandero, Sergio
    Hill, Joseph A.
    JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (03): : 1109 - 1118
  • [39] Impact of Endothelial-Specific FoxO1 Depletion on the Development of Metabolic Dysfunction in Obesity
    Rudnicki, Martina
    Abdifarkosh, Ghoncheh
    Roudier, Emilie
    Nwadozi, Emmanuel
    Haas, Tara
    FASEB JOURNAL, 2017, 31
  • [40] Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1
    Peng, Shiming
    Xiao, Wen
    Ju, Dapeng
    Sun, Baofa
    Hou, Nannan
    Liu, Qianlan
    Wang, Yanli
    Zhao, Haijiao
    Gao, Chunchun
    Zhang, Song
    Cao, Ran
    Li, Pengfei
    Huang, Huanwei
    Ma, Yongfen
    Wang, Yankai
    Lai, Weiyi
    Ma, Zhixiong
    Zhang, Wei
    Huang, Song
    Wang, Hailin
    Zhang, Zhiyuan
    Zhao, Liping
    Cai, Tao
    Zhao, Yong-Liang
    Wang, Fengchao
    Nie, Yongzhan
    Zhi, Gang
    Yang, Yun-Gui
    Zhang, Eric Erquan
    Huang, Niu
    SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (488)